Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGOS phase 3 first-line study in extensive-stage small cell lung cancer
CTR20251471Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- May 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bms-986012 + nivolumab, atezolizumab, carboplatin, etoposide in small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Started May 2025; status: active.
02
Drugs
bms-986012 + nivolumabatezolizumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20251471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251471.